Back to Awarded Treatment Trials
Awarded Trial: 01-STN-010
Grant ID
01-STN-010
Illness
Schizophrenia
Primary Drug/Intervention
Dehydroepiandrosterone (DHEA)
Primary Dosage
400 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Jarskog
Sample Size
30
Duration of Study Period for Each Subject
6 weeks
Outcome Measurements
PANSS, CGI. AIMS
Results
Dehydroepiandrosterone (DHEA) is a naturally secreted neurosteroid that is known to enhance NMDA receptor neurotransmission, possibly through agonist activity at the sigma receptor. 30 male subjects with schizophrenia or schizoaffective disorder that had persistent symptoms with prior adequate trials of antipsychotics were randomized to adjunctive DHEA or placebo. PANSS total change scores between baseline and 6 weeks did not differ between subjects who received DHEA versus placebo. Likewise, no differences emerged between the groups on the positive subscale, the negative subscale, general psychopathology, CGI, and AIMS.
Publication
N/A
Link
N/A
PI Name
L. Fredrik Jarskog
Degree
MD
Center
Department of Psychiatry
Institution
University of North Carolina at Chapel Hill
Address
CB # 7160, Neurosciences Hospital
City or Town
Chapel Hill
State or Province
NC
Zip or Postal Code
27599
Country
USA
Email Address
jarskog@med.unc.edu